WENA anewmeds.com: רווח נקי למניה ב-12 החודשים האחרונים

The young biotech management of Anew Medical, Inc. (WENA) focuses on neurodegeneration therapy in an effort to attract venture capital. Earnings per share over the last four quarters, with data sourced from GURU.Markets, demonstrates current viability, where the 0.00 indicator expresses the state of the metric. Scientific alliances with laboratories are developing gene therapy for ALS, opening access to a massive market lacking effective medications.
פילוחי מדדים פיננסיים ומדדי שוק עבור Anew Medical (WENA)

For Anew Medical, Inc. (WENA), the 12-month net income per share trend serves as an indicator of operational viability. This metric correlates the company's total profit with the total number of issued shares. This calculation allows an investor to assess the real return on each share without quarterly distortions. The current working capital deficit and the freeze on gene development make this indicator a critical marker of solvency. Negative values here signal a high risk of liquidation for the micro-cap biotech.